Cardio Diagnostics' Breakthrough in AI Heart Testing
Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) is a pioneer in AI-driven cardiovascular medicine, and it is concluding the year with remarkable momentum. The Centers for Medicare and Medicaid Services (CMS) has finalized gapfill payment rates for its innovative Epi+Gen CHD and PrecisionCHD tests, which assess both genetic and epigenetic markers associated with coronary heart disease (CHD).
Finalized Medicare Payment Rates
The newly established gapfill payment rate of $854 for both tests symbolically marks an increase from the previous preliminary rates, which stood at $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. Effective from January 1, this payment rate indicates a progressive step towards assuaging treatment costs for patients covered under Medicare.
CEO Meesha Dogan's Perspective
“We are excited about the finalized payment rate,” commented Meesha Dogan, the CEO and co-founder of Cardio Diagnostics. “This highlights our commitment to making advanced cardiovascular tests accessible to Medicare beneficiaries.”
Understanding the Tests
The PrecisionCHD test employs artificial intelligence to support the diagnosis of CHD, analyzing genetic and epigenetic markers. Meanwhile, the Epi+Gen CHD test offers patients insight into their three-year risk of experiencing a CHD event, such as a heart attack. Both tests are implemented through a simple blood draw, providing a non-invasive and efficient approach to cardiovascular health assessment. Importantly, the tests have already been assigned dedicated CPT Proprietary Laboratory Analysis codes from the American Medical Association, which will take effect on April 1, 2024.
The Impact of Cardiovascular Disease
The approval of these gapfill payment rates is a crucial milestone for Cardio Diagnostics, facilitating widespread Medicare reimbursement. Cardiovascular disease continues to be a prevalent issue in the U.S., accounting for over 370,000 deaths in a recent year. Particularly concerning is the impact on individuals aged 65 and older, among whom heart disease remains the leading cause of mortality. This underscores the urgent need for early detection and intervention strategies.
Importance of Early Detection
Early identification of cardiovascular risks can enable timely interventions, potentially averting severe incidents like heart attacks or strokes. By effectively recognizing and addressing the disease in its initial stages, Cardio Diagnostics aims to significantly reduce the progression of CHD among patients.
Expanding Access to Life-Saving Tests
This year, Cardio Diagnostics has proactively worked to enhance the accessibility of its tests. The company has formed partnerships with 15 new healthcare provider organizations nationwide, thereby broadening availability of the Epi+Gen CHD and PrecisionCHD tests to their patient population. These partnerships span various medical specialties and care models and cover key regions including the South, Northeast, Midwest, and West.
Community Collaborations
Significantly, Cardio Diagnostics has joined forces with the YMCA of East Tennessee to implement a program dedicated to heart disease prevention. With over 40,000 members, the YMCA will facilitate educational initiatives aimed at equipping individuals with proactive strategies for heart health. Furthermore, Cardio Diagnostics will offer clinical tests at discounted rates to those enrolled in the program.
Looking Ahead
As healthcare professionals across the United States increasingly adopt evidence-based methodologies for cardiovascular management, the tests from Cardio Diagnostics are gaining recognition as vital tools for enhancing heart health. With a definitive Medicare rate projected for 2026 and additional partnerships in the pipeline, Cardio Diagnostics is poised for a transformative year ahead.
Frequently Asked Questions
What is Cardio Diagnostics Holdings Inc known for?
Cardio Diagnostics specializes in AI-powered cardiovascular medicine, focusing on providing advanced tests for coronary heart disease.
What are the Epi+Gen CHD and PrecisionCHD tests?
These are AI-driven tests that analyze genetic and epigenetic markers to assess the risk of coronary heart disease.
Why are the Medicare payment rates significant?
These rates enhance patient access to essential cardiovascular tests and enable broader reimbursement for healthcare providers.
How does early detection benefit patients?
Early detection of cardiovascular issues can lead to timely interventions, reducing the risks of serious events like heart attacks.
What partnerships is Cardio Diagnostics involved in?
Recently, Cardio Diagnostics partnered with 15 new healthcare providers and the YMCA of East Tennessee to expand access to their tests.
